BioRestorative Secures FDA Type B Meeting to Discuss Accelerated Approval Pathway for BRTX-100 Stem Cell Therapy
Key Insights
BioRestorative Therapies has been granted a Type B meeting with the FDA scheduled for mid-December to discuss an accelerated Biologics License Application approval pathway for BRTX-100 in chronic lumbar disc disease (search).
The company plans to present consistently positive safety and efficacy signals from its ongoing Phase 2 clinical trial and request an accelerated timeline for entering Phase 3 trials.
BRTX-100 is a novel autologous mesenchymal stem cell therapy that received Fast Track designation from the FDA in February 2025 for treating chronic lumbar disc disease (search).
BioRestorative Therapies has secured a critical Type B meeting with the U.S. Food and Drug Administration to discuss a potential accelerated Biologics License Application approval pathway for its lead stem cell therapy BRTX-100 in treating chronic lumbar disc disease (search). The meeting, scheduled for mid-December, represents a significant regulatory milestone for the Fast-Track-designated program.
Regulatory Strategy and Clinical Progress
During the upcoming FDA meeting, BioRestorative plans to present consistently positive safety and efficacy signals from its ongoing Phase 2 clinical trial of BRTX-100. "We plan on discussing the consistently positive safety and efficacy signals from our ongoing Phase 2 clinical trial of BRTX-100 in cLDD, as demonstrated by every new data analysis completed to-date," said Lance Alstodt, Chief Executive Officer of BioRestorative.
The company also intends to request an accelerated timeline for entering a Phase 3 trial to support its BLA application. In accordance with standard industry practice, BioRestorative will wait to provide further updates until it receives and reviews the written meeting minutes from the FDA.
Fast Track Designation and Regulatory Advantages
The FDA granted Fast Track designation to the BRTX-100 Phase 2 clinical trial for chronic lumbar disc disease (search) treatment in February 2025. This designation facilitates development and expedites review of investigational treatments designed to treat serious conditions with significant unmet medical needs. Benefits include early and frequent FDA interactions during clinical development, with potential eligibility for Priority Review and Accelerated BLA Approval.
Addressing Significant Unmet Medical Need
Chronic lumbar disc disease (search) represents a substantial healthcare burden in the United States. At least 80% of adults experience at least one episode of lower back pain (search) during their lifetime, making it the most common cause of disability among Americans between 45 and 65 years of age. The condition imposes the highest economic burden on the U.S. healthcare system.
Current standard of care involves conservative non-surgical approaches or surgical interventions targeting symptomatic relief and musculoskeletal stabilization. However, there is currently no clinical therapy targeting the reversal of disc degeneration or addressing intervertebral disc cell homeostasis.
BRTX-100 Therapeutic Approach
BRTX-100 is a novel cell-based therapeutic engineered to target areas of the body with limited blood flow. The therapy is formulated from autologous cultured mesenchymal stem cells (search) collected from the patient's bone marrow using proprietary technology. The production process involves collecting bone marrow, isolating and culturing stem cells, and cryopreserving the cells.
In an outpatient procedure, BRTX-100 is injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face surgical intervention.
Current Clinical Trial Design
The safety and efficacy of BRTX-100 in treating chronic lumbar disc disease (search) is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. The trial will enroll up to 99 eligible subjects at up to 16 clinical sites in the United States, with subjects randomized 2:1 to receive either BRTX-100 or placebo.
BioRestorative has also obtained FDA Investigational New Drug clearance to evaluate BRTX-100 in treating chronic cervical discogenic pain (search), expanding the potential therapeutic applications of the platform.